-
1 Comment
Cipla Limited is currently in a long term uptrend where the price is trading 14.9% above its 200 day moving average.
From a valuation standpoint, the stock is 26.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Cipla Limited's total revenue rose by 18.2% to $52B since the same quarter in the previous year.
Its net income has increased by 113.1% to $7B since the same quarter in the previous year.
Finally, its free cash flow grew by 8.8% to $16B since the same quarter in the previous year.
Based on the above factors, Cipla Limited gets an overall score of 5/5.
Exchange | NSE |
---|---|
CurrencyCode | INR |
ISIN | INE059A01026 |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Market Cap | 1T |
---|---|
PE Ratio | 24.81 |
Beta | 0.38 |
Target Price | 1640.919 |
Dividend Yield | 0.8% |
Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CIPLA.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025